| Objective:Endometriosis (abbreviated form of a name endometriosis, EMs) is a common disease frequently-occurring disease and difficult disease of childbearing age women, In recently years, morbidity of this disease markedly improved. Endometriosis is a benign disease be provided other characteristics with proliferation, infiltration, diffusion and repeated attacks, it has some of similar the biological behaviors of cancer. At present, Western medicine treatment of EMS currently not found a very good way, be in common using hormonal and surgical therapies, but there is high recurrence rate and side effects. A large number of clinical practice and experimental studies have shown that the end of Dracorhodin has a blood circulation heals bruises, Sanjie relieve pain effects, treatment of endometriosis has a certain effect. To further explore the Pharmacological of Dracorhodin treat endometriosis, SD rats were studied by using modified autologous transplantation established rat model of endometriosis, with a single flavor fed ealy at the end Dracorhodin gavage treatment, testing the use of the drug after the EMs Model Rat P450A, VEGF expression in rats in the model changes, from the Dracorhodin at the end of the treatment of endometriosis of the mechanism of action, and further into a Chinese medicine treatment of endometriosis provide experimental basis for clinical application.Methods:Use the SD of cleaner-class healthy rats are sexually mature unmated female rats weighing 190～220g, a total of 70. Use of self-transplant rat model was established by EMs, constant temperature 24℃, free diet feeding 15 days later, were randomly killed 12 were observed in rats after modeling whether the pathology proved successful. And then randomly divided into five groups, the model group 11, sham operation group 11, mifepristone group of 12 rats, high-dose group 12 Dracorhodin, Dracorhodin low-dose group 12 animals. Two of these were given a single flavor Dracorhodin low end, high two-dose (respectively 0.27mg/g,1.48mg/g) gavage treatment, mifepristone group were given 25mg/g gavage; model group and sham-operated group was given 0.01mg/g distilled water. The component model rats were injected drug volume 2ml, daily gavage administration of a second, consecutive administration of 18 days. Fasting for 1 day were killed, ectopic endometrial tissue, histopathological observation of the various groups internal and the impact of endometriosis lesions in rats, and then detected by immunohistochemistry in rat tissues of P450A, VEGF levels of expression, Finally were statistically analyzed.Results:1. Pathology confirmed the abdominal transplantation of autologous endometrial endometriosis rat model of modeling success,transplant tissue survival rate of 91.67%.2. EMs rats ectopic endometrium eye view larger, after a single herb medicine Dracorhodinat the end intervene after treatment grafts volume significantly reduced (P<0.05), there is significant difference between them.3. Histopathology, treatment group showed the ectopic endometrial growth was inhibited, the basic atrophy or endometrial tissue degeneration and necrosis. Quantitative analysis of the treatment group was significantly lower than the size of ectopic endometrial control group, but each treatment group no significant difference between groups (p> 0.05). Conclusion:1. Modified autologous transplantation can be effective establishment of rat model of endometriosis.2. EMs rat model of eutopic and ectopic endometrial expression of P450A and the levels of VEGF different, there is its heterogeneity.3. Single-flavor Dracorhodin group by reducing the size of ectopic endometrium and suppress angiogenesis and inhibit rat model of endometriosis of the occurrence and development.4. P450A, VEGF in the pathogenesis of endometriosis has played an important role in single-flavor Dracorhodin can reduce the endometriosis model rats of the P450A and the ectopic endometrial expression levels of VEGF.Subject words:Endometriosis; Dracorhodin; Endometriosis rat modle; Immunohistochemistry; Aromatasecytoehrome p450; Vaseular endothelial growth factor...
|
PDF Full Text Request